Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214347 | 0.98 | CNR2 (0.72) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5212240 | 0.97 | CNR2 (0.71) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5214933 | 0.93 | CNR2 (0.82) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5213034 | 0.90 | CNR2 (0.85) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5249860 | 0.88 | CNR2 (0.68) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5212675 | 0.88 | CNR2 (0.85) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5212579 | 0.87 | CNR2 (0.77) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5212670 | 0.87 | CNR2 (0.84) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14007484 | 0.86 | CNR2 (0.86) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5214894 | 0.86 | CNR2 (0.81) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | claimed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1565442-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004029026-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP3A4 1047/4885CYP2D6 872/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | CNR2 1/4885CYP3A4 659/4885CYP2D6 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.